Drug-induced sedation endoscopy (DISE) classification systems: a systematic review and meta-analysis

AbstractThe aim of this systematic review was to perform qualitative and quantitative analysis on the toxic effects of chloroquine (CQ) and hydroxychloroquine (HCQ) on skeletal muscles. We designed the study according to PRISMA guidelines. Studies for qualitative and quantitative analyses were selected according to the following inclusion criteria: English language; size of sample (> 5 patients), adult (> age of 18) patients, treated with CQ/HCQ for inflammatory diseases, and presenting and not presenting with toxic effects on skeletal muscles. We collected data published from 1990 to April 2020 using PubMed, Cochrane Library, EMBASE, and SciELO. Risk of bias for observational studies was assessed regarding the ROBIN-I scale. Studies with less than five patients (case reports) were selected for an additional qualitative analysis. We used the software Comprehensive Meta-Analysis at the confidence level of 0.05. We identified 23 studies for qualitative analysis (17 case-reports), and five studies were eligible for quantitative analysis. From case reports, 21 patients presented muscle weakness and confirmatory biopsy for CQ/HCQ induced myopathy. From observational studies, 37 patients out of 1,367 patients from five studies presented muscle weakness related to the use of CQ/HCQ, and 252 patients presented elevated levels of muscle enzymes (aldolase, creatine phosphokinase, and lactate dehydrogenase). Four studies presented data on 34 patients with confirmatory biopsy for drug-induced myopathy. No study presented randomized samples. The chronic use of CQ/HCQ may be a risk for drug-induced myopathy. There is substantiated need for proper randomized trials and controlled prospective studies needed to assess the clinical and subclinical stages of CQ/HCQ -induced muscle myopathy.

Download Full-text

Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2019-314422 ◽

2019 ◽

Vol 104 (8) ◽

pp. 1077-1084 ◽

Cited By ~ 11

Author(s):

Jeany Q Li ◽

Thomas Welchowski ◽

Matthias Schmid ◽

Matthias Marten Mauschitz ◽

Frank G Holz ◽

...

Keyword(s):

Systematic Review ◽

Macular Degeneration ◽

Meta Analysis ◽

Resource Planning ◽

Classification Systems ◽

Age Related Macular Degeneration ◽

Population Projections ◽

Age Related ◽

Pooled Prevalence ◽

Incidence Studies

Background/AimsAge-related macular degeneration (AMD) is the main cause of visual impairment and blindness in Europe. A further increase in the number of affected persons is expected and current European data are needed for healthcare resource planning.MethodsWe performed a systematic review on the prevalence and incidence of AMD based on the meta-analysis of observational studies in epidemiology guideline. Meta-analysis and meta-regression on time-trends, age, countries, regions, sex and classification systems for AMD were performed. Based on Eurostat population projections, the pooled prevalence estimates were extrapolated to the year 2050.ResultsTwenty-two prevalence and four incidence studies published since 1996 were included. Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively. A significant increase in prevalence was seen in older populations. In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6). Overall, the number of EU inhabitants with any AMD is expected to increase from 67 to 77 million until 2050. Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050.ConclusionsApproximately 67 million people in the EU are currently affected by any AMD and, due to population ageing, this number is expected to increase by 15% until 2050. Monitoring and treatment of people with advanced disease stages will require additional healthcare resources and thorough healthcare planning in the years and decades to come.

Download Full-text

Sa1558 Risk of Non-Steroidal Anti-Inflammatory Drugs-Related Serious Drug-Induced Liver Injury: A Systematic Review and Meta-Analysis

Gastroenterology ◽

10.1016/s0016-5085(16)33601-0 ◽

2016 ◽

Vol 150 (4) ◽

pp. S1066

Author(s):

Sakkarin Chirapongsathorn ◽

Chayakrit Krittanawong ◽

Ann M. Farrell ◽

Mohammad H. Murad ◽

Patrick Kamath

Keyword(s):

Systematic Review ◽

Liver Injury ◽

Meta Analysis ◽

Drug Induced ◽

Drug Induced Liver Injury ◽

Inflammatory Drugs ◽

Anti Inflammatory

Download Full-text

Granulocyte-Colony-Stimulating Factor Effectively Shortens Recovery Duration in Anti-Thyroid-Drug-Induced Agranulocytosis: A Systematic Review and Meta-Analysis

Frontiers in Endocrinology ◽

10.3389/fendo.2019.00789 ◽

2019 ◽

Vol 10 ◽

Author(s):

Yonghui Wang ◽

Xiaoying Li ◽

Qian Yang ◽

Wei Wang ◽

Yanan Zhang ◽

...

Keyword(s):

Systematic Review ◽

Meta Analysis ◽

Granulocyte Colony Stimulating Factor ◽

Colony Stimulating Factor ◽

Drug Induced ◽

Recovery Duration ◽

Stimulating Factor

Download Full-text

Drug-induced liver injury secondary to biologic medications in inflammatory bowel disease: meta-analysis and systematic review

Archives of Medical Science - Aging ◽

10.5114/amsa.2021.107804 ◽

2021 ◽

Vol 4 (1) ◽

pp. 14-22

Author(s):

Eyad Gadour ◽

Zeinab Hassan

Keyword(s):

Systematic Review ◽

Inflammatory Bowel Disease ◽

Liver Injury ◽

Bowel Disease ◽

Meta Analysis ◽

Drug Induced ◽

Drug Induced Liver Injury ◽

Inflammatory Bowel

Download Full-text

S1194 Risk of Drug-Induced Liver Injury in Patients With Chronic Hepatitis B and Active Tuberculosis Co-Infection: A Systematic Review and Meta-Analysis

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000778308.95440.75 ◽

2021 ◽

Vol 116 (1) ◽

pp. S554-S555

Author(s):

Christina Chou ◽

Nicolette Veracruz ◽

Amit S. Chitnis ◽

Robert Wong

Keyword(s):

Systematic Review ◽

Chronic Hepatitis ◽

Liver Injury ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Meta Analysis ◽

Active Tuberculosis ◽

Drug Induced ◽

Drug Induced Liver Injury

Download Full-text

Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis

BMJ Open ◽

10.1136/bmjopen-2018-027940 ◽

2019 ◽

Vol 9 (8) ◽

pp. e027940 ◽

Cited By ~ 5

Author(s):

Seungwon Yang ◽

Se Jung Hwang ◽

Jung Yun Park ◽

Eun Kyoung Chung ◽

Jangik I Lee

Keyword(s):

Systematic Review ◽

Liver Injury ◽

Genetic Polymorphisms ◽

Fixed Effects ◽

Meta Analysis ◽

Organic Anion ◽

Close Monitoring ◽

Drug Induced ◽

Slow Acetylator ◽

Drug Induced Liver Injury

ObjectivesThe objective of this study was to investigate the association between genetic polymorphisms of N-acetyltransferase 2 (NAT2), cytochrome P450 2E1 (CYP2E1), glutathione S-transferase (GST) and solute carrier organic anion transporter family member 1B1 (SLCO1B1) and the risk of anti-tuberculosis drug-induced liver injury (ATDILI).DesignSystematic review and meta-analysis.Data sourcesPubMed, Embase, Web of Science and Cochrane Reviews databases were searched through April 2019.Eligibility criteriaWe included case-control or cohort studies investigating an association between NAT2, CYP2E1, GST or SLCO1B1 polymorphisms and the ATDILI risk in patients with tuberculosis.Data extraction and synthesisThree authors screened articles, extracted data and assessed study quality. The strength of association was evaluated for each gene using the pooled OR with a 95% CI based on the fixed-effects or random-effects model. Sensitivity analysis was performed to confirm the reliability and robustness of the results.ResultsFifty-four studies were included in this analysis (n=26 for CYP2E1, n=35 for NAT2, n=19 for GST, n=4 for SLCO1B1). The risk of ATDILI was significantly increased with the following genotypes: CYP2E1 RsaI/PstI c1/c1 (OR=1.39, 95% CI 1.06 to 1.83), NAT2 slow acetylator (OR=3.30, 95% CI 2.65 to 4.11) and GSTM1 null (OR=1.30, 95% CI 1.12 to 1.52). No significant association with ATDILI was found for the genetic polymorphisms of CYP2E1 DraI, GSTT1, GSTM1/GSTT1, SLCO1B1 388A>G and SLCO1B1 521T>C (p>0.05).ConclusionsATDILI is more likely to occur in patients with NAT2 slow acetylator genotype, CYP2E1 RsaI/PstI c1/c1 genotype and GSTM1 null genotype. Close monitoring may be warranted for patients with these genotypes.

Download Full-text

Drug-induced sleep endoscopy compared with systematic adenotonsillectomy in the management of obstructive sleep apnoea in children: a systematic review and meta-analysis protocol

BMJ Open ◽

10.1136/bmjopen-2018-028242 ◽

2019 ◽

Vol 9 (9) ◽

pp. e028242 ◽

Cited By ~ 1

Author(s):

Anne-Sophie Prévost ◽

Mathieu Hylands ◽

Mireille Gervais ◽

Jean-Paul Praud ◽

Marie-Claude Battista ◽

...

Keyword(s):

Systematic Review ◽

Obstructive Sleep Apnoea ◽

Data Extraction ◽

Meta Analysis ◽

Sleep Apnoea ◽

Published Data ◽

Sleep Endoscopy ◽

Drug Induced ◽

Drug Induced Sleep Endoscopy ◽

Obstructive Sleep

IntroductionObstructive sleep apnoea affects up to 6% of children worldwide. Although current guidelines recommend systematic tonsillectomy and adenoidectomy, many children do not benefit from these interventions. Drug-induced sleep endoscopy (DISE) allows the dynamic evaluation of patients’ airways to identify the specific anatomic sites of obstruction. This intervention can potentially guide subsequent invasive procedures to optimise outcomes and minimise the number of children exposed to unnecessary operations.Methods and analysisWe will identify randomised controlled trials and controlled observational studies comparing DISE-directed interventions to systematic tonsillectomy and adenoidectomy in paediatric populations. We will search MEDLINE, EMBASE, CINAHL, CENTRAL as well as clinical trial registries and conference proceedings (initial electronic search date 9 October 2018). Screening, data extraction and risk of bias assessments will be performed in duplicate by independent reviewers. We will use the Grading of Recommendations Assessment, Development and Evaluation approach to assess the overall quality of evidence and present our results.Ethics and disseminationEthics approval is not required for this systematic review of published data. This review will be presented according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We will present our findings at otorhinolaryngology conferences and publish a report in a peer-reviewed journal.PROSPERO registration numberCRD42018085370.

Download Full-text